THU0604 CARPAL TUNNEL SYNDROME: CAN ULTRASOUND PREDICT RESPONSE TO STEROID INJECTION?. (June 2019)

• Record Type: Journal Article
• Authors: Donaghy, Cathy; Elliott, Ashley; Pendleton, Adrian; Benson, Claire; Aston, Kerry; O'neill, Aidan; Stewart, Roger; Leith, Mark; Beattie, Colette
• Is Part Of: Annals of the rheumatic diseases. Volume 78(2019)Supplement 2
• Page Start: 594
• Page End: 594
• Publication Date: 2019-06
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2019-eular.1197
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Carpal tunnel syndrome (CTS) is the commonest nerve entrapment disorder of the upper limb. Diagnosis is often clinical, based on a suggestive history and physical examination. Neurophysiological studies correlate closely with clinical evaluation. The use of ultrasound has been evaluated, and a feature which consistently supports a clinical diagnosis of CTS is increased cross sectional area (CSA) of the median nerve within the carpal tunnel. Local injection with corticosteroid is generally accepted as the next step in those who remain symptomatic after conservative treatment with splinting and nonsteroidal anti-inflammatory drugs. If this is unsuccessful referral for consideration of surgery should be considered. Objectives: To evaluate the utility of ultrasound in the assessment of CTS and identify predictors of response to injection. Methods: Patients were recruited via primary care referrals to the rheumatology department. Inclusion criteria were age over 18 years, appropriate symptoms in the distribution of the median nerve for at least 3 months, and positive nerve conduction studies (NCS). Patients with evidence of thenar atrophy were excluded. At initial review a full symptom and medical history was taken. A Boston Carpal Tunnel Questionnaire was completed, along with visual analog scale (VAS). Ultrasound assessment was carried out by a rheumatology physician who was blinded to the above information. CSA of the median nerve was measured at the level of the proximal third of the pronator quadratus muscle and the largest CSA within the carpal tunnel. The presence or absence of tenosynovitis, Doppler signal and a bifid median nerve were noted. Steroid injection was carried out under indirect ultrasound guidance with 20mg depomedrone. Follow-up assessment was carried out 12 weeks post-injection. Repeat ultrasound scan was performed to measure the CSA of the median nerve, as before. Repeat Boston Questionnaire and VAS were recorded. After the second assessment those who had not responded adequately were referred on for consideration of surgical release. Results: 52 patients attended for initial assessment, with 47 patients reattending for follow up. 53% of patients were discharged at follow up; the remainder were referred for consideration of surgery. 78.9% of patients met the criteria for defining CTS with a median nerve CSA 0.1cm 2, with 77% meeting this at the entrance to the carpal tunnel, and 55.8% at the level of the pronator quadratus muscle. A bifid nerve was noted in 12 patients. There was no statistically significant relationship between the initial size of the median nerve on ultrasound and the change in Boston score. There was a statistically significant correlation between a decrease in the size of the median nerve at the entrance to the carpal tunnel and an improvement in the Boston score (r=0.42, p-value 0.003). There was no correlation between change in median nerve measurement and final outcome (discharged or referred to surgery). There was no relationship between the degree of entrapment on NCS and pre-test Boston score. There was a significant change in the Boston score of 0.944 post-injection (95% CI 0.41-1.48, p-value 0.001). There was a statistically significant change in the VAS score of 9.87 post-injection (95% CI 0.78-18.95, p-value 0.03). No patients demonstrated evidence of surrounding tenosynovitis or positive power doppler signal. Conclusion: There is an overall improvement in symptoms of CTS, based on the Boston questionnaire, following corticosteroid injection. There is a clear role for the use of ultrasound to confirm diagnosis of CTS in symptomatic patients by measuring the CSA of the median nerve at the entrance to the carpal tunnel. There are no definite ultrasound or clinical prognostic indicators of response to injection. References: Disclosure of Interests: : Cathy Donaghy: None declared, Ashley Elliott Speakers bureau: Novartis, Adrian Pendleton: None declared, Claire Benson: None declared, Kerry Aston: None declared, Aidan O'Neill: None declared, Roger Stewart: None declared, Mark Leith: None declared, Colette Beattie: None declared